» Articles » PMID: 24338023

Novel Piperazine-based Compounds Inhibit Microtubule Dynamics and Sensitize Colon Cancer Cells to Tumor Necrosis Factor-induced Apoptosis

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2013 Dec 17
PMID 24338023
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

We recently identified a series of mitotically acting piperazine-based compounds that potently increase the sensitivity of colon cancer cells to apoptotic ligands. Here we describe a structure-activity relationship study on this compound class and identify a highly active derivative ((4-(3-chlorophenyl)piperazin-1-yl)(2-ethoxyphenyl)methanone), referred to as AK301, the activity of which is governed by the positioning of functional groups on the phenyl and benzoyl rings. AK301 induced mitotic arrest in HT29 human colon cancer cells with an ED50 of ≈115 nm. Although AK301 inhibited growth of normal lung fibroblast cells, mitotic arrest was more pronounced in the colon cancer cells (50% versus 10%). Cells arrested by AK301 showed the formation of multiple microtubule organizing centers with Aurora kinase A and γ-tubulin. Employing in vitro and in vivo assays, tubulin polymerization was found to be slowed (but not abolished) by AK301. In silico molecular docking suggests that AK301 binds to the colchicine-binding domain on β-tubulin, but in a novel orientation. Cells arrested by AK301 expressed elevated levels of TNFR1 on their surface and more readily activated caspases-8, -9, and -3 in the presence of TNF. Relative to other microtubule destabilizers, AK301 was the most active TNF-sensitizing agent and also stimulated Fas- and TRAIL-induced apoptosis. In summary, we report a new class of mitosis-targeting agents that effectively sensitizes cancer cells to apoptotic ligands. These compounds should help illuminate the role of microtubules in regulating apoptotic ligand sensitivity and may ultimately be useful for developing agents that augment the anti-cancer activities of the immune response.

Citing Articles

Discovery of novel arylamide derivatives containing piperazine moiety as inhibitors of tubulin polymerisation with potent liver cancer inhibitory activity.

Shi X, Jiao H, Zhang J, Tian X, Guo D, Gao J J Enzyme Inhib Med Chem. 2023; 38(1):2237701.

PMID: 37489043 PMC: 10392279. DOI: 10.1080/14756366.2023.2237701.


Green Approach Toward Triazole Forming Reactions for Developing Anticancer Drugs.

Rastogi S, Ciliberto V, Trevino M, Campbell B, Brittain W Curr Org Synth. 2023; 21(4):380-420.

PMID: 37157212 DOI: 10.2174/1570179420666230508125144.


Discovery of Simple Diacylhydrazine-Functionalized Cinnamic Acid Derivatives as Potential Microtubule Stabilizers.

Zhou X, Fu Y, Zou Y, Meng J, Ou-Yang G, Ge Q Int J Mol Sci. 2022; 23(20).

PMID: 36293224 PMC: 9604255. DOI: 10.3390/ijms232012365.


Eriodictyol mediated selective targeting of the TNFR1/FADD/TRADD axis in cancer cells induce apoptosis and inhibit tumor progression and metastasis.

Debnath S, Sarkar A, Mukherjee D, Ray S, Mahata B, Mahata T Transl Oncol. 2022; 21:101433.

PMID: 35462210 PMC: 9046888. DOI: 10.1016/j.tranon.2022.101433.


A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization.

Ebenezer O, Shapi M, Tuszynski J Int J Mol Sci. 2022; 23(7).

PMID: 35409361 PMC: 8999808. DOI: 10.3390/ijms23074001.


References
1.
Eum H, Vallabhaneni R, Wang Y, Loughran P, Stolz D, Billiar T . Characterization of DISC formation and TNFR1 translocation to mitochondria in TNF-α-treated hepatocytes. Am J Pathol. 2011; 179(3):1221-9. PMC: 3157172. DOI: 10.1016/j.ajpath.2011.05.046. View

2.
Chari R . Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2007; 41(1):98-107. DOI: 10.1021/ar700108g. View

3.
Kramer A, Neben K, Ho A . Centrosome replication, genomic instability and cancer. Leukemia. 2002; 16(5):767-75. DOI: 10.1038/sj.leu.2402454. View

4.
Correale P, Tagliaferri P, Fioravanti A, Del Vecchio M, Remondo C, Montagnani F . Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008; 14(13):4192-9. DOI: 10.1158/1078-0432.CCR-07-5278. View

5.
Rieder C, Maiato H . Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell. 2004; 7(5):637-51. DOI: 10.1016/j.devcel.2004.09.002. View